2022. ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER . World Bulletin of Public Health. 12, (Jul. 2022), 66–69.